Additionally, our results also suggest that bone destruction caused by tumor invasion in human OSCC is through RANKL-RANK/NF-κB/NFATc1 pathway36, which can be suppressed by sorafenib through releasing OPG from osteoblasts to suppress RANKL binding to RANK (Fig. 5). This evidence concerns the gene TNFSF11 and neoplasm.